• More than 500 labs worldwide have purchased Doxorubicin from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
• Doxorubicin is an anthracycline antibiotic. It is used in the treatment of a wide range of cancers. Di Marco, A., et al. \"Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.\" Cancer Chemother. Rep. 53: 33-37 (1969).
• Doxorubicin inhibited DNA and RNA but not protein synthesis in intact cells. Momparler, R.L., et al. \"Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells.\" Cancer Res. 36: 2891-2895 (1976).
• Doxorubicin-conjugated HIV(P4/D10) antibody neutralized HIV-1IIIB and inhibited HIV replication in vitro. It also protected mice from challenge with HIV-1IIIB/MuLV in vivo. Johansson, S., et al. \"Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.\" AIDS 20: 1911-1915 (2006).
• Combination with estradiol was found to enhance the apoptotic action of doxorubicin in estrogen-resistant MCF-7/LS cells but not in the estrogen-dependent MCF-7 breast cancer cells. NF-κB may be a potential target for estradiol and doxorubicin in the therapy of the resistant breast cancer. Scherbakov, A.M., et al. \"Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.\" Biosci. Rep. Jul 27 (2010) [Epub ahead of print].
• When patients were treated for breast or ovarian cancer, lymphoma, myeloma or sarcoma, the risk of cardiotoxicity was significantly greater with doxorubicin-containing regimens and bolus administration than non-anthracycline regimens. Smith, L.A., et al. \"Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.\" BMC Cancer 10: 337 (2010).
• Doxorubicin hydrochloride is the active ingredient in the drug sold under the tradenames Adriamycin PFS, Adriamycin RDF, or Rubex®. This drug has been approved in at least one country for use in patients with a wide range of cancers. NOTE: THE DOXORUBICIN, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ADRIAMYCIN OR RUBEX®, AND IS NOT FOR HUMAN USE.
• Our doxorubicin product is the hydrochloride salt, whose CAS number is given above. The CAS number of the free base is 23214-92-8.
• Other CAS numbers previously assigned to doxorubicin, namely 23257-17-2, 24385-08-8, 25311-50-6, and 29042-30-6, have been deleted by CAS and are no longer in use.
• We note that one of our competitors, Medical Isotopes, as of October 31, 2011, is claiming 99.7% purity for its Doxorubicin, Hydrochloride Salt. This claim is not credible in general chemical terms for this complex organic compound, nor in terms of the sensitivity and reproducibility of generally utilized analytical techniques.
• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.

Related Terms: